Acute myeloïde leukemie (AML)
HOVON 145: European Intergroup Trial on panobinostat maintenance after HSCT for high-risk AML and MDS - A randomized, multicenter phase III study to assess the efficacy of panobinostat maintenance therapy vs. standard of care following allogeneic stem cell transplantation in patients with high-risk AML or MDS (ETAL-4 / HOVON-145)
Myelodysplastisch syndroom (MDS)
COMMANDS: A phase 3, open-label, randomized study to compare the efficacy and safety of luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk myelodysplastic syndromes (MDS) in ESA naïve subjects who require red blood cell transfusions
Chronische myeloïde leukemie (CML)
HOVON 142: Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing nilotinib versus imatinib with switch to nilotinib in absence of optimal response
Auto-immuun hemolytische anemie (AIHA)
DRAIHA: Data registry of autoimmune hemolytic anemia, to improve diagnostic testing for the development of personalized treatment protocols in AIHA patients
Supportive care
AFFECT-2: Efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan
Paroxysmale nachtelijke hemoglobinurie (PNH)
DAHLIA / ABP959: A randomized, double-blind, active-controlled phase 3 study evaluating the efficacy and safety of ABP 959 compared with eculizumab in adult subjects with paroxysmal nocturnal hemoglobinuria (PNH)
Ga terug naar de algemene homepage Studieinformatie.